KLF4 and neoplasm: Therefore, targeting KLF4 to favorably alter the phenotypic ratio of TAMs, characterized by a reduction in M2 macrophages and an increase in M1 macrophages, represents a promising therapeutic strategy to promote anti‐tumor immunity [130].